225 related articles for article (PubMed ID: 29743334)
1. Randomised controlled trial of high versus ad libitum water intake in patients with autosomal dominant polycystic kidney disease: rationale and design of the DRINK feasibility trial.
El-Damanawi R; Lee M; Harris T; Mader LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Burrows A; Woznowski P; Ben-Shlomo Y; Karet Frankl FE; Hiemstra TF
BMJ Open; 2018 May; 8(5):e022859. PubMed ID: 29743334
[TBL] [Abstract][Full Text] [Related]
2. High water vs. ad libitum water intake for autosomal dominant polycystic kidney disease: a randomized controlled feasibility trial.
El-Damanawi R; Lee M; Harris T; Cowley LB; Bond S; Pavey H; Sandford RN; Wilkinson IB; Karet Frankl FE; Hiemstra TF
QJM; 2020 Apr; 113(4):258-265. PubMed ID: 31665476
[TBL] [Abstract][Full Text] [Related]
3. Randomised controlled trial to determine the efficacy and safety of prescribed water intake to prevent kidney failure due to autosomal dominant polycystic kidney disease (PREVENT-ADPKD).
Wong ATY; Mannix C; Grantham JJ; Allman-Farinelli M; Badve SV; Boudville N; Byth K; Chan J; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Haloob I; Harris DCH; Hawley CM; Hill J; Howard K; Howell M; Jiang SH; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Peduto A; Rangan A; Roger SD; Sud K; Torres V; Vilayur E; Rangan GK
BMJ Open; 2018 Jan; 8(1):e018794. PubMed ID: 29358433
[TBL] [Abstract][Full Text] [Related]
4. Low-Osmolar Diet and Adjusted Water Intake for Vasopressin Reduction in Autosomal Dominant Polycystic Kidney Disease: A Pilot Randomized Controlled Trial.
Amro OW; Paulus JK; Noubary F; Perrone RD
Am J Kidney Dis; 2016 Dec; 68(6):882-891. PubMed ID: 27663039
[TBL] [Abstract][Full Text] [Related]
5. Prescribed Water Intake in Autosomal Dominant Polycystic Kidney Disease.
Rangan GK; Wong ATY; Munt A; Zhang JQJ; Saravanabavan S; Louw S; Allman-Farinelli M; Badve SV; Boudville N; Chan J; Coolican H; Coulshed S; Edwards ME; Erickson BJ; Fernando M; Foster S; Gregory AV; Haloob I; Hawley CM; Holt J; Howard K; Howell M; Johnson DW; Kline TL; Kumar K; Lee VW; Lonergan M; Mai J; McCloud P; Pascoe E; Peduto A; Rangan A; Roger SD; Sherfan J; Sud K; Torres VE; Vilayur E; Harris DCH
NEJM Evid; 2022 Jan; 1(1):EVIDoa2100021. PubMed ID: 38319283
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment.
Zittema D; Boertien WE; van Beek AP; Dullaart RP; Franssen CF; de Jong PE; Meijer E; Gansevoort RT
Clin J Am Soc Nephrol; 2012 Jun; 7(6):906-13. PubMed ID: 22516290
[TBL] [Abstract][Full Text] [Related]
7. Short-term Effects of Tolvaptan in Individuals With Autosomal Dominant Polycystic Kidney Disease at Various Levels of Kidney Function.
Boertien WE; Meijer E; de Jong PE; ter Horst GJ; Renken RJ; van der Jagt EJ; Kappert P; Ouyang J; Engels GE; van Oeveren W; Struck J; Czerwiec FS; Oberdhan D; Krasa HB; Gansevoort RT
Am J Kidney Dis; 2015 Jun; 65(6):833-41. PubMed ID: 25600953
[TBL] [Abstract][Full Text] [Related]
8. Water prescription in autosomal dominant polycystic kidney disease: a pilot study.
Wang CJ; Creed C; Winklhofer FT; Grantham JJ
Clin J Am Soc Nephrol; 2011 Jan; 6(1):192-7. PubMed ID: 20876670
[TBL] [Abstract][Full Text] [Related]
9. RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study.
Ryu H; Park HC; Oh YK; Sangadi I; Wong A; Mei C; Ecder T; Wang AY; Kao TW; Huang JW; Rangan GK; Ahn C
BMJ Open; 2020 Feb; 10(2):e034103. PubMed ID: 32034027
[TBL] [Abstract][Full Text] [Related]
10. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease.
Barash I; Ponda MP; Goldfarb DS; Skolnik EY
Clin J Am Soc Nephrol; 2010 Apr; 5(4):693-7. PubMed ID: 20167686
[TBL] [Abstract][Full Text] [Related]
11. Urine and plasma osmolality in patients with autosomal dominant polycystic kidney disease: reliable indicators of vasopressin activity and disease prognosis?
Casteleijn NF; Zittema D; Bakker SJ; Boertien WE; Gaillard CA; Meijer E; Spithoven EM; Struck J; Gansevoort RT
Am J Nephrol; 2015; 41(3):248-56. PubMed ID: 25926129
[TBL] [Abstract][Full Text] [Related]
12. Relative Validity of a Beverage Frequency Questionnaire Used to Assess Fluid Intake in the Autosomal Dominant Polycystic Kidney Disease Population.
Mannix C; Rangan A; Wong A; Zhang J; Allman-Farinelli M; Rangan G
Nutrients; 2018 Aug; 10(8):. PubMed ID: 30096903
[TBL] [Abstract][Full Text] [Related]
13. Tolvaptan use in children and adolescents with autosomal dominant polycystic kidney disease: rationale and design of a two-part, randomized, double-blind, placebo-controlled trial.
Schaefer F; Mekahli D; Emma F; Gilbert RD; Bockenhauer D; Cadnapaphornchai MA; Shi L; Dandurand A; Sikes K; Shoaf SE
Eur J Pediatr; 2019 Jul; 178(7):1013-1021. PubMed ID: 31053954
[TBL] [Abstract][Full Text] [Related]
14. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
Meijer E; Drenth JP; d'Agnolo H; Casteleijn NF; de Fijter JW; Gevers TJ; Kappert P; Peters DJ; Salih M; Soonawala D; Spithoven EM; Torres VE; Visser FW; Wetzels JF; Zietse R; Gansevoort RT;
Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
[TBL] [Abstract][Full Text] [Related]
15. Metformin Therapy in Autosomal Dominant Polycystic Kidney Disease: A Feasibility Study.
Brosnahan GM; Wang W; Gitomer B; Struemph T; George D; You Z; Nowak KL; Klawitter J; Chonchol MB
Am J Kidney Dis; 2022 Apr; 79(4):518-526. PubMed ID: 34391872
[TBL] [Abstract][Full Text] [Related]
16. Venglustat, a Novel Glucosylceramide Synthase Inhibitor, in Patients at Risk of Rapidly Progressing ADPKD: Primary Results of a Double-Blind, Placebo-Controlled, Phase 2/3 Randomized Clinical Trial.
Gansevoort RT; Hariri A; Minini P; Ahn C; Chapman AB; Horie S; Knebelmann B; Mrug M; Ong ACM; Pei YPC; Torres VE; Modur V; Antonshchuk I; Perrone RD
Am J Kidney Dis; 2023 May; 81(5):517-527.e1. PubMed ID: 36535535
[TBL] [Abstract][Full Text] [Related]
17. Rationale and design of the TEMPO (Tolvaptan Efficacy and Safety in Management of Autosomal Dominant Polycystic Kidney Disease and its Outcomes) 3-4 Study.
Torres VE; Meijer E; Bae KT; Chapman AB; Devuyst O; Gansevoort RT; Grantham JJ; Higashihara E; Perrone RD; Krasa HB; Ouyang JJ; Czerwiec FS
Am J Kidney Dis; 2011 May; 57(5):692-9. PubMed ID: 21333426
[TBL] [Abstract][Full Text] [Related]
18. Urine Concentrating Capacity, Vasopressin and Copeptin in ADPKD and IgA Nephropathy Patients with Renal Impairment.
Zittema D; Casteleijn NF; Bakker SJ; Boesten LS; Duit AA; Franssen CF; Gaillard CA; Gansevoort RT
PLoS One; 2017; 12(1):e0169263. PubMed ID: 28081165
[TBL] [Abstract][Full Text] [Related]
19. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
[TBL] [Abstract][Full Text] [Related]
20. TOLVAPTAN USE IN SEVERE NEONATAL AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): THE PHARMACEUTICAL CHALLENGE.
Olalekan K; Fox A; Gilbert R
Arch Dis Child; 2016 Sep; 101(9):e2. PubMed ID: 27540244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
